Skip to main content
SpringerLink
Log in

Liraglutide in obesity: a guide to its use in the EU

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Liraglutide (Saxenda®; 3 mg dose), a glucagon-like peptide-1 receptor agonist, is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥30 kg/m2 or ≥27 to <30 kg/m2 in the presence of at least one bodyweight-related co-morbidity (e.g. dysglycaemia, dyslipidaemia, hypertension, obstructive sleep apnoea). Clinical data in these patient populations indicates that subcutaneous liraglutide 3.0 mg once daily provides clinically meaningful (i.e. 5–10 % reduction) and sustained reductions in bodyweight and is generally well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Obesity and overweight: fact sheet no. 311. Geneva: World Health Organization; 2015.

  2. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–96.

    Article  PubMed  Google Scholar 

  4. Bray GA. Why do we need drugs to treat the patient with obesity? Obesity. 2013;21(5):893–9.

    Article  PubMed  Google Scholar 

  5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.

    Article  PubMed  Google Scholar 

  6. Wright F, Boyle S, Baxter K, et al. Understanding the relationship between weight loss, emotional well-being and health-related quality of life in patients attending a specialist obesity weight management service. J Health Psychol. 2013;18(4):574–86.

    Article  PubMed  Google Scholar 

  7. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641–9.

    PubMed Central  PubMed  Google Scholar 

  8. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. Partial update of CG43. London: National Institute for Health and Care Excellence; 2014.

  9. Barja-Fernandez S, Leis R, Casanueva FF, et al. Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss. Drug Des Dev Therapy. 2014;8:2391–400.

    CAS  Google Scholar 

  10. World Gastroenterology Organization global guideline: obesity. Milwaukee: World Gastroenterology Organization; 2011.

  11. Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75(8):899–910.

    Article  CAS  PubMed  Google Scholar 

  12. Scott LJ. Liraglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(18):2161–74.

    Article  CAS  PubMed  Google Scholar 

  13. Saxenda: summary of product characteristics. London: European Medicines Agency; 2015.

  14. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258–66.

    Article  CAS  PubMed  Google Scholar 

  15. Van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obesity. 2014;38(6):784–93.

    Article  Google Scholar 

  16. Inoue K, Maeda N, Kashine S, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:109.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Fujishima Y, Maeda N, Inoue K, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obesity. 2013;37(11):1443–51.

    Article  CAS  Google Scholar 

  19. Pi-Sunyer FX, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

    Article  PubMed  Google Scholar 

  20. Blackman A, Foster G, Zammit G, et al. Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE Sleep Apnoea trial [abstract no. 184]. Diabetologia. 2014;57(1 Suppl 1):S85.

  21. Bode B, DeFronzo R, Bergenstal R, et al. Effect of liraglutide 3.0/1.8 mg on body weight and cardiometabolic risk factors in overweight/obese adults with type 2 diabetes: SCALE Diabetes randomised, double-blind, 56-week trial [abstract no. 181]. Diabetologia. 2014;57(1 Suppl 1):S83.

  22. Golden J. FDA briefing document NDA 206321: liraglutide injection, 3 mg. Silver Spring: US Food and Drug Administration; 2014.

    Google Scholar 

  23. DeFronzo R, Bergenstal R, Bode B, et al. Effect of liraglutide 3.0 mg cessation on efficacy and safety/tolerability after 56 weeks’ treatment in obese/overweight adults with type 2 diabetes: SCALE Diabetes [abstract no. 76]. Diabetologia. 2014;57(1 Suppl 1):S38–9.

  24. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–16.

    Article  CAS  PubMed  Google Scholar 

  25. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obesity. 2012;36(6):843–54.

    Article  CAS  Google Scholar 

  26. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement for shaping America’s health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30(6):1647–52.

    Article  PubMed  Google Scholar 

  27. Wilding JPH, Astrup A, Fujioka K, et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial [abstract no. T4:RS2.3]. Obes Facts. 2014;7(Suppl 1):15.

    Google Scholar 

  28. Davies MJ, Bergenstal R, Bode B, et al. Liraglutide 3.0 mg for weight management in obese/overweight adults with type 2 diabetes: SCALE Diabetes 56-week randomised, double-blind, placebo-controlled trial [abstract no. 39]. Diabetologia. 2014;57(1 Suppl 1):S22–3.

    Google Scholar 

  29. Saxenda® liraglutide (rDNA) injection: US prescribing information. Plainsboro: Novo Nordisk; 2015.

  30. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96(3):853–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The review was updated from Drugs 2015;75(8):899–910 [11], and was reviewed by: M. C. Mancini, Sao Paulo University, Endocrinology and Metabology Service, Obesity and Metabolic Syndrome Group, Sao Paulo, Brazil; J. L. Pérez-Castrillón, Rio Hortega University Hospital, University of Valladolid, Institute of Endocrinology and Nutrition, Valladolid, Spain; T. Tzotzas, Agios Pavlos General Hospital, Thessaloniki, Greece; W. M. Valencia, Geriatrics Research, Education and Clinical Center (GRECC) and Endocrine Section, Miami VA Medical Center, Miami, FL, USA. During the peer review process, the manufacturer of liraglutide was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Lesley J. Scott

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

L. Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Liraglutide in obesity: a guide to its use in the EU. Drugs Ther Perspect 31, 334–340 (2015). https://doi.org/10.1007/s40267-015-0241-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0241-x

Keywords

Search

Navigation